Congress Passes FY 2026 Bill: What $47.2B for NIH Means for Grants

Hook

On February 3, 2026, President Trump signed into law the Consolidated Appropriations Act (H.R. 7148) for fiscal year 2026, delivering $47.2 billion in funding for the NIH—a slight increase over FY 2025 and a decisive rebuttal to deep cuts proposed by the White House. Despite bipartisan relief over protected research spending, grant seekers are facing significant barriers to accessing this funding due to new administrative restrictions and delays.

Context

The FY 2026 federal budget cycle was among the most contentious in recent memory. The Trump administration proposed almost $18 billion in NIH reductions and nearly $5 billion in cuts to the National Science Foundation, sparking urgent advocacy from universities, medical centers, and research nonprofits. Congress ultimately rejected these cuts, maintaining not just NIH funding but also stabilizing investments for the CDC, HHS, rural health initiatives, maternal and behavioral health, and community health centers. Organizations like the Association of American Medical Colleges publicly praised lawmakers for supporting these research priorities (source).

However, new hurdles have emerged. Following the bill’s passage, the Office of Management and Budget (OMB) imposed temporary spending restrictions: For 30 days after enactment (through March 5, 2026), NIH could only spend on critical functions like salaries. Now, every NIH institute must submit detailed spend plans for OMB approval before disbursing much of their appropriated funding. This extra layer of review, together with the aftershocks of a 43-day federal shutdown in late 2025, has created a bottleneck in grant administration and review.

Impact

For Researchers

The immediate outlook is mixed. NIH has issued only about 800 new and competing awards so far—barely a third of the typical figure for this point in the year. Moreover, the number of active Notices of Funding Opportunities (NOFOs) has been slashed in half, and a new 16-step internal review process slows every funding decision. Some clinical trial network grants are being extended into FY 2027 as a stopgap, but other programs risk an under-spend if approvals remain sluggish.

Grant applicants, especially those working on investigator-initiated proposals or clinical consortia, face longer waits and uncertainty over when—or even whether—funding will flow. As Walter Koroshetz (former head of NIH Neuroscience) observed, new funding notices "would need to be on the street by now" for agencies to deploy their full appropriations by fiscal year-end.

For Nonprofits & Community Health Organizations

The FY 2026 Act renews and modestly improves support for rural health programs, community centers, and maternal/behavioral health programs. While core funding is secure, those seeking new grants for multi-institutional collaborations or health equity initiatives may encounter fewer, more competitive opportunities. The administrative slowdown could be especially acute for smaller organizations reliant on timely project starts.

For Small Businesses

Small business innovation grant (SBIR/STTR) applicants should note that delays in NOFO releases and start-up of new awards are likely through mid-2026. Projects targeting NIH priority areas like drug development, diagnostic tools, or digital health innovations can expect tighter timetables for both proposal submission and review.

Action: What Grant Seekers Should Do Right Now

• Monitor Notice Boards Rigorously: Check NIH Funding Opportunities and Grants.gov daily—NOFOs may post on compressed timelines to meet fiscal year spending mandates.
• Connect with Program Officers: Reach out proactively to NIH or federal agency contacts about anticipated RFPs, review cycles, and timelines. Transparency is improving, but programs may not be able to offer specifics until OMB approvals are finalized.
• Prepare Proposals Now: Use this administrative lull to sharpen and finalize proposals, complete registrations (eRA Commons, SAM.gov, Grants.gov), and assemble supplementary materials. When awards open, deadlines may be tight and competition fierce.
• Review Extended and Bridge Funding: Investigate whether your current or recent award qualifies for extension or bridge funding during this transition—especially for clinical studies and multi-site projects.

Outlook

While congressional action averted catastrophic cuts and stabilizes health research funding through September 2026, the administrative headwinds facing NIH and other agencies are real. Stakeholders hope these restrictions will ease after OMB’s initial review period ends, but full implementation could remain slow through the spring. If bottlenecks persist, Congress and advocacy groups may apply pressure for faster disbursement or legal adjustments. For now, staying alert, being proactive, and maintaining flexibility is the best way forward.

Granted AI offers up-to-date alerts and strategic guidance to help you find and compete for emerging grants during this period of administrative change.